Segment Information

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Information

14.Segment Information

The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The Company manages its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker uses the revenues and earnings (losses) of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.

The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.

The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were $143,816 and $143,889 as of March 31, 2024 and December 31, 2023, respectively.

Financial information by segment for the three months ended March 31, 2024 and 2023 is as follows:

	Three Months Ended March 31, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,287	$	13,394	$	-			$	14,681
Cost of revenues (excluding amortization of acquired intangible assets)		-			177		1,463		-				1,640
Direct expenses		5,465			416		4,414		9,576				19,871
Segment contribution	$	(5,465	)	$	694	$	7,517		(9,576	)			(6,830	)
Indirect expenses									546		(a)		546
Loss from operations												$	(7,376	)
(a) Components of other
Amortization									546
Total other								$	546

	Three Months Ended March 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	1,357	$	2,578		$	-			$	3,935
Cost of revenues (excluding amortization of acquired intangible assets)		-			472		1,531			-				2,003
Direct expenses		40,162			344		3,009			11,155				54,670
Segment contribution		(40,162	)		541		(1,962	)		(11,155	)			(52,738	)
Indirect expenses										11,132		(b)		11,132
Loss from operations													$	(63,870	)
(b) Components of other
Change in fair value of contingent consideration liability										(18,932	)
Change in fair value of contingent stock consideration										(110	)
Goodwill impairment										29,633
Amortization										541
Total other									$	11,132